All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Epkinly breaks ground in Phase III FL trial

Genmab and AbbVie’s subcutaneous bispecific antibody Epkinly (epcoritamab) has met its dual primary endpoints as a second-line combination therapy in…
Alfasigma sets stage for Jyseleca in axSpA after Phase III win

Alfasigma plans to engage with regulators to seek approval for Jyseleca (filgotinib) in active axial spondyloarthritis (axSpA) following a successful…
Sarepta allowed to continue US Elevidys shipments

After two weeks in the regulatory wringer, Sarepta Therapeutics has been given clearance to continue shipments of its Duchenne muscular…
CHMP rejects Elevidys in latest setback for Sarepta

Sarepta has suffered another regulatory setback after the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP)…
Novo Nordisk defeated in Wegovy patent dispute by Viatris

Danish weight-loss giant Novo Nordisk has lost a US patent to generics manufacturer Viatris. A federal district court in Delaware…

UK enacts law to decentralise manufacture of personalised treatments

The UK Government has passed legislation to decentralise the manufacture of personalised medicines, allowing them to be prepared in facilities…
Sarepta halts Elevidys shipments following FDA pressure

Sarepta Therapeutics has yielded to the US Food and Drug Administration (FDA), agreeing to suspend shipments of Elevidys (delandistrogene moxeparvovec)…
Sarepta refuses to pull gene therapy despite FDA request

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the US Food and…
GSK’s Blenrep faces setback as FDA cancer committee votes against approval

The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab…
PEPFAR funding protection offers “hope” for people living with HIV

The White House’s decision to safeguard $400m in President's Emergency Plan for AIDS Relief (PEPFAR) funding to support the global…